Anju Wadhwa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anju Wadhwa has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- David Meybin Wilson
Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA
318 shared publications - Robert Richard Flavell
Department of Radiology and Biomedical Imaging University of California, San Francisco San Francisco California USA
318 shared publications - Anil Parsram Bidkar
Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA
317 shared publications - Henry F. VanBrocklin
Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
317 shared publications - Kondapa Naidu Bobba
University of California, San Francisco 1 Department of Radiology and Biomedical Imaging San Francisco, California
317 shared publications - Youngho Seo
University of California
317 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S14 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S14. Comparison of influx and efflux rates of [89Zr]PEG-DFB4 and [89Zr]PEG-DFB1-TLZ3 conjugates in different subcutaneous tumor models (n = 4, mean ± SD). *Prior published data.6
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S14 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S14. Comparison of influx and efflux rates of [89Zr]PEG-DFB4 and [89Zr]PEG-DFB1-TLZ3 conjugates in different subcutaneous tumor models (n = 4, mean ± SD). *Prior published data.6
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S33 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S33. Body weight measurements for the MM.1S disseminated tumor-bearing animals treated with [225Ac]Macropa-PEG4-YS5-MMAE.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S33 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S33. Body weight measurements for the MM.1S disseminated tumor-bearing animals treated with [225Ac]Macropa-PEG4-YS5-MMAE.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S10. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ for 89Zr labeled nanocarriers in nude mice bearing LTL-545 patient derived xenograft (PDX) of tumors at 96 h postinjection. (n = 4, mean ± SD)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S10. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ for 89Zr labeled nanocarriers in nude mice bearing LTL-545 patient derived xenograft (PDX) of tumors at 96 h postinjection. (n = 4, mean ± SD)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S2. Pilot PET/CT studies in prostate, pancreatic, and colorectal cancer models to measure the enhanced permeability retention effect using [89Zr]PEG-DFB1-TLZ3.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S2. Pilot PET/CT studies in prostate, pancreatic, and colorectal cancer models to measure the enhanced permeability retention effect using [89Zr]PEG-DFB1-TLZ3.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S34 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S34. Body weight measurements for the RPMI disseminated tumor bearing animals treated with [225Ac]Macropa-PEG4-YS5-MMAE.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S34 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S34. Body weight measurements for the RPMI disseminated tumor bearing animals treated with [225Ac]Macropa-PEG4-YS5-MMAE.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S13 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S13. Organ biodistribution analysis data in %ID/Organ tissue for 89Zr labeled nanocarriers at 96 h in mice model bearing LTL-610 subcutaneous tumors. (n = 4)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S13 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S13. Organ biodistribution analysis data in %ID/Organ tissue for 89Zr labeled nanocarriers at 96 h in mice model bearing LTL-610 subcutaneous tumors. (n = 4)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S29 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S29. PET/CT imaging of relapsed tumors using [89Zr]DFO-YS5, showing axial, coronal, and maximum intensity projection (MIP) views. The imaging demonstrates uptake of [89Zr]DFO-YS5 in tumors, confirming the presence of CD46 expression on relapsed tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S29 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S29. PET/CT imaging of relapsed tumors using [89Zr]DFO-YS5, showing axial, coronal, and maximum intensity projection (MIP) views. The imaging demonstrates uptake of [89Zr]DFO-YS5 in tumors, confirming the presence of CD46 expression on relapsed tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S21 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S21. PET imaging and biodistribution of [134Ce]Macropa-PEG4-YS5 in 22Rv1 tumor-bearing mice. Axial, coronal PET/CT, and MIP images of 22Rv1 tumor-bearing mice were acquired at 24, 48, 96, and 168 hours following intravenous administration of [134Ce]Macropa-PEG4-YS5, illustrating tracer biodistribution and tumor uptake over time.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S21 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
Figure S21. PET imaging and biodistribution of [134Ce]Macropa-PEG4-YS5 in 22Rv1 tumor-bearing mice. Axial, coronal PET/CT, and MIP images of 22Rv1 tumor-bearing mice were acquired at 24, 48, 96, and 168 hours following intravenous administration of [134Ce]Macropa-PEG4-YS5, illustrating tracer biodistribution and tumor uptake over time.